17,261 trials
Hemophilia A or B
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), TEAEs by Severity, and Serious Adverse Events (SAEs) (All Causality and Treatment-Related) — 5; 2…
Refractory Metastatic Colorectal Cancer
Primary: Immune-Related Overall Response Rate (irORR) — 0 percentage of participants
Becker Muscular Dystrophy
Primary: Plasma Follistatin
Chronic Lymphocytic Leukemia
Primary: Participants With a Response — 23 Participants
Lewy Body Dementia
Primary: Change From Baseline in the Continuity of Attention (CoA) Composite Score of the Cognitive Drug Research Computerized Cognition Battery (CDR-CCB) — 1.04; 0.15; 0.96…
Healthy
Primary: Area Under the Viral Load-Time Curve (VL-AUC) of Respiratory Syncytial Virus (RSV) by Quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR) — 0; 236…
Advanced Cancer
Primary: Number of Participants With Adverse Events (AEs) — 41; 21; 42 Participants
Pulmonary Arterial Hypertension · Pulmonary Hypertension · Interstitial Lung Disease
Primary: Change From Baseline Though Week 16 in 6-Minute Walk Distance (6MWD) for Bardoxolone Methyl Compared to Placebo — 32.5; 24; 3.4; -3.2 meters — p=0.8133
Liver Cancer
Primary: Number of Participants With Toxicity Related to Electrochemotherapy — 20; 0; 0; 4 Participants
Pancreatic Adenocarcinoma · Resectable Pancreatic Carcinoma
Primary: Overall Survival (OS) — 23.2; 23.6 Months — p=.15
Blepharoptosis
Primary: Humphrey Visual Field — 9.8; 12.1; 11.1; 16.1 Points seen
Leukemia, Lymphocytic, Chronic, B-Cell
Primary: Overall Response Rate (ORR) — 33.3 percentage of participants
Non-Small-Cell Lung Cancer
Primary: Objective Response Rate (ORR) by PD-L1 Positive and Negative Levels - Part 1 — 41.3; 14.9 Percentage of participants
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Primary: Percentage of Participants With Cytogenetic Response (Complete Cytogenetic Response and Major Cytogenetic Response) to STI571 — 29.6; 37.2; 45.8; 45.4 percentage of…
Philadelphia Positive Chronic Myeloid Leukemia · Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia
Primary: Percentage of Participants With Hematologic Response in Accelerated Phase Chronic Myeloid/Myelogenous Leukemia — 64.9; 74.7 percentage of participants